SCHEDULE 13G: Citadel Entities Disclose Significant Passive Stake in Aardvark Therapeutics, Inc.
Beneficial Ownership Disclosure
Citadel Advisors, Citadel Securities, and Kenneth Griffin have jointly filed a Schedule 13G, disclosing a combined passive beneficial ownership of 5.6% in Aardvark Therapeutics, Inc.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively reported beneficial ownership of 1,152,375 shares of Aardvark Therapeutics, Inc. Common Stock, representing 5.4% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively reported beneficial ownership of 40,596 shares, representing 0.2% of the class.
- Kenneth Griffin, as the controlling person, reported an aggregate beneficial ownership of 1,192,971 shares, representing 5.6% of the class.
- The filing indicates that the shares were acquired for investment purposes and not to change or influence control of Aardvark Therapeutics, Inc.
- The percentages are based on 21,384,377 shares outstanding as of February 14, 2025, according to the issuer's prospectus filed on February 13, 2025.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing (Schedule 13G) disclosing passive beneficial ownership, which typically does not convey positive or negative sentiment about the issuer's performance or prospects.
Positives
- A significant passive stake of 5.6% in Aardvark Therapeutics, Inc. has been disclosed by Citadel entities, including Citadel Advisors and Kenneth Griffin, potentially signaling confidence from a major institutional investor.
Future Outlook
NA
Management Comments
- The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant passive institutional stake may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2023-10-13 | Date of power of attorney filing by Citadel Advisors LLC for Allakos Inc., referenced for Kenneth Griffin's signature. |
| 2025-02-13 | Date of Aardvark Therapeutics, Inc.'s prospectus filing with the SEC, which stated the number of shares outstanding. |
| 2025-02-14 | Date of event which requires the filing of this Schedule 13G (crossing the 5% beneficial ownership threshold). |
| 2025-02-24 | Date of filing of this Schedule 13G. |
Keywords
Aardvark Therapeutics, Citadel, Schedule 13G, beneficial ownership, institutional investment, common stock, SEC filing, passive stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.